Admescope – a Oulu, Finland-headquartered company providing absorption, distribution, metabolism, and excretion (ADME) and toxicology services – yesterday announced its acquisition of the CRO MetaSafe.
Based in Södertälje, Sweden, MetaSafe focuses on metabolite identification studies during drug development.
Juho Alatalo, VP of marketing and sales at Admescope told us the acquisition broadens the company’s services for clinical stage metabolism studies.
The deal – financial terms of which were not disclosed – also expands Admescope's physical presence to Stockholm area, providing a larger recruitment pool to support future growth, Alatalo explained.
“For the near future, Metasafe AB will operate as a fully owned subsidiary of Admescope, shifting to operate under Admescope brand at autumn,” he added.
The companies will immediately start aligning research procedures "and other practical matters."
"We are very excited about the acquisition and to welcome the experienced experts of Metasafe to Admescope," Alatalo added. "We are certain that this acquisition will help us serve all of our customers even better, offering a broader portfolio of services for their projects at clinical stages."